<DOC>
	<DOC>NCT01549548</DOC>
	<brief_summary>The main purpose of this protocol is to provide expanded access to the study drug (Ponatinib/AP24534) for people with imatinib-, dasatinib-, and nilotinib- resistant/intolerant Philadelphia Chromosome Positive (Ph+) Leukemias. The other purpose of this protocol is to monitor the safety of the study drug in people with Ph+ Leukemias that have not responded to prior treatment.</brief_summary>
	<brief_title>Compassionate Use Ponatinib</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Ponatinib</mesh_term>
	<criteria>Signed and dated informed consent Cytogenetic or PCRbased diagnosis of any phase of Ph+ acute lymphoblastic leukemia (ALL) and documented resistance or intolerance to imatinib and a second TKI (nilotinib, dasatinib, bosutinib) Eastern Cooperative Oncology Group(ECOG) performance status of 02 Washout from prior antiproliferative or antileukemia treatment: 3 days for hydroxyurea/anagrelide and tyrosine kinase inhibitors &lt; Grade 2 or baseline recovery from prior therapy related toxicities (except alopecia) At least 3 months post allogeneic stem cell transplantation Able to take oral capsules reliably AST/ALT less than or equal to 2.5 times ULN, or less than 5 times ULN if attributable to involvement of leukemia No active clinical or radiographic pancreatitis At least 18 years of age Willingness of male and female subjects to use reliable methods of birth control (when applicable) Subjects with Philadelphia Chromosome and BCRABLnegative chronic myeloid leukemia (CML) Major surgery or radiotherapy within 7 days before the first dose of Ponatinib (recovery from any previous surgery should be complete before day 1) Clinically significant active/uncompensated or uncontrolled cardiac disease (active congestive heart failure; uncontrolled angina or hypertension; myocardial infarction in the past 3 months; clinically significant untreated ventricular arrhythmia; diagnosed or suspected congenital or acquired prolonged QT syndrome; unexplained syncope; history of prolonged QTc) Prolonged QTc (&gt; 0.48 sec) Pregnant or breastfeeding women Evidence of serious active infection, or significant medical or psychiatric illness Known seropositivity to HIV, or current acute or chronic Hepatitis B or Hepatitis C (antigen positive), cirrhosis, or clinically significant abnormal lab finding that would, in the investigator's judgment, make the subject inappropriate for this study Prior resistance to Ponatinib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>CML</keyword>
</DOC>